CFB
CORT icon

Cullen/Frost Bankers’s Corcept Therapeutics CORT Stock Holding History

Cullen/Frost Bankers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17K Hold
25
– – ﹤0.01% 1285
2026
Q1 		$1.01K Hold
25
– – ﹤0.01% 1306
2025
Q4 		$870 Hold
25
– – ﹤0.01% 1312
2025
Q3 		$2.08K Hold
25
– – ﹤0.01% 1225
2025
Q2 		$1.83K Hold
25
– – ﹤0.01% 1186
2025
Q1 		$2.86K Hold
25
– – ﹤0.01% 1121
2024
Q4 		$1.26K Buy
+25
New +$1.31K ﹤0.01% 1208

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cullen/Frost Bankers's CORT Position: Q2 2026 in Review

Cullen/Frost Bankers held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 25 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #1285.

Cullen/Frost Bankers first reported a position in CORT in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.86K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Cullen/Frost Bankers held 25 shares of Corcept Therapeutics worth $2.17K as of Q2 2026.
  • Cullen/Frost Bankers left its Corcept Therapeutics share count unchanged in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1285 holding.
  • Cullen/Frost Bankers first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Cullen/Frost Bankers's Corcept Therapeutics position peaked at $2.86K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.